Sign inJoin waitlistJoin the waitlist

Rachel Salit

Associate Professor, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology
2007–2008
Internal Medicine
2004–2007
Loyola University Chicago Stritch School of Medicine
2000–2004
Psychology, Magna Cum Laude, Duke University
1992–1996

Research

Cord-Blood Transplantation in Patients with Minimal Residual Disease
New England Journal of Medicine · 2016 · 380 citations
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant…
Journal of Clinical Oncology · 2017 · 269 citations
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
Blood · 2016 · 237 citations

Bart Scott
20 papers
Stephanie Lee
18 papers
Paul Carpenter
14 papers
Joachim Deeg
11 papers
Mary Flowers
11 papers
Colleen Delaney
10 papers
Filippo Milano
10 papers · 10 as a resident
Elizabeth Krakow
9 papers
Michael Bishop
8 papers
Phuong Vo
8 papers
Brenda Sandmaier
7 papers
Karen Syrjala
7 papers

Clinical trials

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Principal investigator · Recruiting · Phase 2
Fred Hutchinson Cancer Center
2026–2030
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
Principal investigator · Active not recruiting · Phase 2
Fred Hutchinson Cancer Center
2025–2026
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Principal investigator · Recruiting · Phase 2
Fred Hutchinson Cancer Center
2021–2029
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Principal investigator · Active not recruiting · Phase 2
Fred Hutchinson Cancer Center
2020–2030